Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm

Cancer Family

Epithelial Neoplasm

CI-CAN-00000016Explore in graph →

Non-malignant7,525 active trials118 approved drugs1,152 evidence items

NCIt: C3709

Overview
Statistics
Survival
Genomics314
Variants & evidence1152
Drugs206
Trials26878
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (916)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 51–75 of 916 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
· J Clin Oncol · 2025 · PMID 39250535 · validated civic_curation pubmed
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
· N Engl J Med · 2025 · PMID 40293180 · validated civic_curation pubmed
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
· J Clin Oncol · 2025 · PMID 40923280 · validated civic_curation pubmed
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
· N Engl J Med · 2025 · PMID 41104928 · validated civic_curation pubmed
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
· J Clin Oncol · 2015 · PMID 25667280 · validated civic_curation pubmed
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
· Cancer Discov · 2017 · PMID 28183697 · validated civic_curation pubmed
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
· Ann Oncol · 2019 · PMID 30624546 · validated

Showing 51–75 of 916 publications

← Previous
1
2
3
4
…
37
Next →

civic_curation

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

· Lancet Oncol · 2012 · PMID 22452895 · validated civic_curation pubmed

Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.

· Horm Metab Res · 2014 · PMID 24570209 · validated civic_curation pubmed

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

· Clin Endocrinol (Oxf) · 2014 · PMID 24354346 · validated civic_curation pubmed

Integrated molecular analysis of clear-cell renal cell carcinoma.

· Nat Genet · 2013 · PMID 23797736 · validated civic_curation pubmed

Comprehensive molecular characterization of clear cell renal cell carcinoma.

· Nature · 2013 · PMID 23792563 · validated civic_curation pubmed

Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.

· Nat Genet · 2014 · PMID 24658004 · validated cbioportal_study pubmed

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

· N Engl J Med · 2001 · PMID 11248153 · validated civic_curation pubmed

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

· J Clin Oncol · 2005 · PMID 15911866 · validated civic_curation pubmed

DNAJB1-PRKACA is specific for fibrolamellar carcinoma.

· Mod Pathol · 2015 · PMID 25698061 · validated civic_curation pubmed

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

· J Clin Oncol · 2014 · PMID 25024077 · validated civic_curation pubmed

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

· N Engl J Med · 2015 · PMID 25693012 · validated civic_curation pubmed

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

· Lancet Oncol · 2010 · PMID 20022809 · validated civic_curation pubmed

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

· N Engl J Med · 2009 · PMID 19692680 · validated civic_curation pubmed

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

· J Clin Oncol · 2017 · PMID 28453411 · validated civic_curation pubmed

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

· Ann Oncol · 2016 · PMID 26768165 · validated civic_curation pubmed

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

· Lancet Oncol · 2017 · PMID 28958504 · validated civic_curation pubmed

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

· N Engl J Med · 2022 · PMID 34534430 · validated civic_curation pubmed

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.

· Clin Cancer Res · 2021 · PMID 33355200 · validated civic_curation pubmed